… of oral anticoagulation therapy for real-world atrial fibrillation patients with an elevated risk
of stroke, highlighting the need for improved therapies for stroke prevention in atrial fibrillation. …

Atrial fibrillation (AF) is the most common significant cardiac rhythm disorder. Oral anticoagulation
(OAC) is recommended by guidelines in the presence of a moderate to high risk of …

… Non-vitamin K antagonist oral anticoagulants (NOACs) are effective and safe alternatives
compared with vitamin K antagonists (VKAs) for thromboembolic prevention in atrial fibrillation (…

… Oral anticoagulation (OAC) is recommended to reduce the risk of stroke associated with
nonvalvular atrial fibrillation … Warfarin is the most widely prescribed oral anticoagulant in the …

… [6] Many randomized controlled studies have demonstrated that oral anticoagulant … the
frequency of oral anticoagulant use in patients with AF, whether oral anticoagulant use was …

… with AF are currently not treated with oral anticoagulants (9-11), as an … oral anticoagulants
in a large population of outpatients with AF starting their treatment at different anticoagulation …

… Suboptimal use of oral anticoagulants in patients with atrial fibrillation is a missed opportunity
to impact on an important cause of thromboembolic stroke. Systematic identification of …

… Using a recently proposed method to determine the optimal intensity of oral anticoagulant
therapy… events occurring in the anticoagulation cohort of the European Atrial Fibrillation Trial, a …

… Oral anticoagulant (OAC) therapy is recommended for the prevention of thromboembolic
events in non-valvular atrial … (VKAs) and nonVKA oral anticoagulants (NOACs), is medication …

… Oral anticoagulants (OAC) are essential for stroke prevention in patients with atrial fibrillation
(AF). The use of conventional OAC, such as a vitamin K antagonist (VKA), reduces stroke …